Sotradecol (sodium tetradecyl sulfate)

No dosing information is available for this tab.

Sodium tetradecyl sulfate is administered only by IV injection. Extravasation should be avoided. (See Administration Precautions under Cautions: Warnings/Precautions.)

Sodium tetradecyl sulfate is commercially available as a 1 or 3% solution in vials (containing a total of 20 or 60 mg, respectively, in each 2-mL vial). Although the drug has been administered as an endovenous foam or microfoam, these preparations are not commercially available in the US and extemporaneous preparation of sodium tetradecyl sulfate foam is not approved by the US Food and Drug Administration (FDA).

Unopened vials of sodium tetradecyl sulfate solution should be stored at 20-25degreesC.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Sodium tetradecyl sulfate solutions that have precipitated or are discolored should not be used.

Sodium tetradecyl sulfate is incompatible with heparin; therefore, the 2 drugs should not be mixed in the same syringe.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

Sodium tetradecyl sulfate is contraindicated in patients with a history of hypersensitivity reactions to the drug or history of allergic conditions. (See Sensitivity Reactions under Cautions: Warnings/Precautions.)

Sodium tetradecyl sulfate is contraindicated in patients with acute superficial thrombophlebitis, valvular or deep vein incompetence, huge superficial veins with wide open communications to deeper veins, phlebitis migrans, or varicosities caused by abdominal and pelvic tumors (unless the tumor has been removed).

The drug also is contraindicated in bedridden patients or patients with acute cellulitis, acute infections, or uncontrolled systemic diseases (e.g., diabetes, toxic hyperthyroidism, tuberculosis, asthma, neoplasm, sepsis, blood dyscrasias, acute respiratory disease, skin disease).

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

Adverse effects reported in patients treated with sodium tetradecyl sulfate include injection site reactions (pain, urticaria, ulceration), discoloration along the path of a sclerosed vein segment (may be permanent), allergic reactions, and mild systemic reactions (headache, nausea, vomiting).

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

Safety and efficacy of sodium tetradecyl sulfate have not been established in pediatric patients.

Category C. (See Users Guide)

There are no adequate and well-controlled studies using sodium tetradecyl sulfate in pregnant women; the drug should be used during pregnancy only if clearly needed and if the benefits outweigh the risks.

It is not known whether sodium tetradecyl sulfate is distributed into human milk. Because many drugs are distributed into milk, sodium tetradecyl sulfate should be used with caution in nursing woman.

No enhanced messaging available.